TY - JOUR
T1 - Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy
AU - Santantonio, Teresa
AU - Medda, E.
AU - Ferrari, C.
AU - Fabris, P.
AU - Cariti, G.
AU - Massari, M.
AU - Babudieri, S.
AU - Toti, M.
AU - Francavilla, R.
AU - Ancarani, F.
AU - Antonucci, G.
AU - Scotto, G.
AU - Di Marco, V.
AU - Pastore, G.
AU - Stroffolini, T.
PY - 2006/11/1
Y1 - 2006/11/1
N2 - Background. The epidemiology of acute hepatitis C has changed during the past decade in Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute infection should be treated. Methods. To evaluate current sources of hepatitis C virus (HCV) transmission in Italy and to assess the rate of and factors associated with chronic infection, we enrolled 214 consecutive patients with newly acquired hepatitis C during 1999-2004. The patients were from 12 health care centers throughout the country, and they were followed up for a mean (± SD) period of 14 ± 15.8 months. Biochemical liver tests were performed, and HCV RNA levels were monitored. Results. A total of 146 patients (68%) had symptomatic disease. The most common risk factors for acquiring hepatitis C that were reported were intravenous drug use and medical procedures. The proportion of subjects with spontaneous resolution of infection was 36%. The average timespan from disease onset to HCV RNA clearance was 71 days (range, 27-173 days). In fact, 58 (80%) of 73 patients with self-limiting hepatitis experienced HCV RNA clearance within 3 months of disease onset. Multiple logistic regression analyses showed that none of the variables considered (including asymptomatic disease) were associated with increased risk of developing chronic hepatitis C. Conclusions. These findings underscore the importance of medical procedures as risk factors in the current spread of HCV infection in Italy. Because nearly all patients with acute, self-limiting hepatitis C-both symptomatic and asymptomatic-have spontaneous viral clearance within 3 months of disease onset, it seems reasonable to start treatment after this time period ends to avoid costly and useless treatment.
AB - Background. The epidemiology of acute hepatitis C has changed during the past decade in Western countries. Acute HCV infection has a high rate of chronicity, but it is unclear when patients with acute infection should be treated. Methods. To evaluate current sources of hepatitis C virus (HCV) transmission in Italy and to assess the rate of and factors associated with chronic infection, we enrolled 214 consecutive patients with newly acquired hepatitis C during 1999-2004. The patients were from 12 health care centers throughout the country, and they were followed up for a mean (± SD) period of 14 ± 15.8 months. Biochemical liver tests were performed, and HCV RNA levels were monitored. Results. A total of 146 patients (68%) had symptomatic disease. The most common risk factors for acquiring hepatitis C that were reported were intravenous drug use and medical procedures. The proportion of subjects with spontaneous resolution of infection was 36%. The average timespan from disease onset to HCV RNA clearance was 71 days (range, 27-173 days). In fact, 58 (80%) of 73 patients with self-limiting hepatitis experienced HCV RNA clearance within 3 months of disease onset. Multiple logistic regression analyses showed that none of the variables considered (including asymptomatic disease) were associated with increased risk of developing chronic hepatitis C. Conclusions. These findings underscore the importance of medical procedures as risk factors in the current spread of HCV infection in Italy. Because nearly all patients with acute, self-limiting hepatitis C-both symptomatic and asymptomatic-have spontaneous viral clearance within 3 months of disease onset, it seems reasonable to start treatment after this time period ends to avoid costly and useless treatment.
UR - http://www.scopus.com/inward/record.url?scp=33750117419&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750117419&partnerID=8YFLogxK
U2 - 10.1086/507640
DO - 10.1086/507640
M3 - Article
C2 - 17029134
AN - SCOPUS:33750117419
VL - 43
SP - 1154
EP - 1159
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 9
ER -